JP2014514308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514308A5 JP2014514308A5 JP2014505381A JP2014505381A JP2014514308A5 JP 2014514308 A5 JP2014514308 A5 JP 2014514308A5 JP 2014505381 A JP2014505381 A JP 2014505381A JP 2014505381 A JP2014505381 A JP 2014505381A JP 2014514308 A5 JP2014514308 A5 JP 2014514308A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- alkynyl
- alkenyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 53
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 41
- 229910052799 carbon Inorganic materials 0.000 claims description 40
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 229910052717 sulfur Inorganic materials 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 36
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 31
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 30
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 29
- 150000001721 carbon Chemical group 0.000 claims description 28
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 24
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims description 24
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 24
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 20
- 239000003112 inhibitor Substances 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 18
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 17
- 125000006736 (C6-C20) aryl group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 12
- 229940035893 uracil Drugs 0.000 claims description 12
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims description 11
- 229940104302 cytosine Drugs 0.000 claims description 10
- 239000002777 nucleoside Substances 0.000 claims description 10
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- -1 R 8 is H Chemical group 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 5
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 5
- 229940122806 Cyclophilin inhibitor Drugs 0.000 claims description 5
- 241000711549 Hepacivirus C Species 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 229940123066 Polymerase inhibitor Drugs 0.000 claims description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical class N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 5
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims description 5
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229940079322 interferon Drugs 0.000 claims description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- DKSVBVKHUICELN-UHFFFAOYSA-N 3-ethoxy-6-[2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy]-1,2-benzoxazole Chemical compound C=1C=C2C(OCC)=NOC2=CC=1OCCC(CC1)CCN1C1=CC=C(C)N=N1 DKSVBVKHUICELN-UHFFFAOYSA-N 0.000 claims description 4
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 229940125400 channel inhibitor Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 claims description 4
- 229960000471 pleconaril Drugs 0.000 claims description 4
- 239000002911 sialidase inhibitor Substances 0.000 claims description 4
- 229940113082 thymine Drugs 0.000 claims description 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 3
- 241000725619 Dengue virus Species 0.000 claims description 3
- 241000710781 Flaviviridae Species 0.000 claims description 3
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 3
- 241000710912 Kunjin virus Species 0.000 claims description 3
- 241000710908 Murray Valley encephalitis virus Species 0.000 claims description 3
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims description 3
- 241000710888 St. Louis encephalitis virus Species 0.000 claims description 3
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 3
- 241000710886 West Nile virus Species 0.000 claims description 3
- 241000710772 Yellow fever virus Species 0.000 claims description 3
- 208000020329 Zika virus infectious disease Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 229940051021 yellow-fever virus Drugs 0.000 claims description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 claims description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims description 2
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229950004244 laninamivir Drugs 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 2
- 229960001084 peramivir Drugs 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229960000888 rimantadine Drugs 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 241000124008 Mammalia Species 0.000 description 3
- 229910019946 S-S Inorganic materials 0.000 description 3
- 229910019939 S—S Inorganic materials 0.000 description 3
- 241000711557 Hepacivirus Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474848P | 2011-04-13 | 2011-04-13 | |
| US61/474,848 | 2011-04-13 | ||
| PCT/US2012/033675 WO2012142523A2 (en) | 2011-04-13 | 2012-04-13 | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014514308A JP2014514308A (ja) | 2014-06-19 |
| JP2014514308A5 true JP2014514308A5 (enExample) | 2015-05-28 |
| JP6043338B2 JP6043338B2 (ja) | 2016-12-14 |
Family
ID=46001834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505381A Expired - Fee Related JP6043338B2 (ja) | 2011-04-13 | 2012-04-13 | 抗ウイルス治療用の１’−置換ピリミジンｎ−ヌクレオシド類似体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8877733B2 (enExample) |
| EP (1) | EP2697241B1 (enExample) |
| JP (1) | JP6043338B2 (enExample) |
| KR (1) | KR20140019832A (enExample) |
| CN (1) | CN103476783A (enExample) |
| AU (1) | AU2012242517B2 (enExample) |
| BR (1) | BR112013026219A2 (enExample) |
| CA (1) | CA2830689A1 (enExample) |
| EA (1) | EA201391264A1 (enExample) |
| ES (1) | ES2744587T3 (enExample) |
| IL (1) | IL228680A0 (enExample) |
| MX (1) | MX2013011915A (enExample) |
| WO (1) | WO2012142523A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| US9676797B2 (en) * | 2015-09-02 | 2017-06-13 | Abbvie Inc. | Anti-viral compounds |
| CA2773773C (en) | 2009-09-21 | 2019-04-23 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
| SI2595980T1 (sl) | 2010-07-22 | 2014-11-28 | Gilead Sciences, Inc. | Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| US20130315868A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | D-amino acid compounds for liver disease |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| WO2014033617A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | 2'-ethynyl nucleoside derivatives for treatment of viral infections |
| WO2014052638A1 (en) * | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| CA2887578A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharamaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
| WO2014099941A1 (en) * | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| EP2935303B1 (en) | 2012-12-21 | 2021-02-17 | Janssen BioPharma, Inc. | 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
| RU2015148010A (ru) * | 2013-04-12 | 2017-05-15 | Ачиллион Фармасютикалз, Инк. | Высокоактивное производное нуклеозида для лечения hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| JP6562908B2 (ja) | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
| WO2015061683A1 (en) * | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
| EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| SMT202100592T1 (it) | 2014-12-26 | 2021-11-12 | Univ Emory | Derivati antivirali della n4-idrossicitidina |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| SI3349758T1 (sl) | 2015-09-16 | 2022-08-31 | Gilead Sciences, Inc. | Postopki za zdravljenje okužb z virusom arenaviridae |
| US11963972B2 (en) | 2016-03-23 | 2024-04-23 | Emory University | Antiviral agents and nucleoside analogs for treatment of Zika virus |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| CN109689672B (zh) | 2016-09-07 | 2023-05-30 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
| EP3555293A4 (en) * | 2016-12-15 | 2020-08-12 | Meharry Medical College | ANTIVIRAL AGENTS |
| GEP20227457B (en) | 2017-02-01 | 2023-01-10 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for treatment of hepatitis c virus |
| KR102460968B1 (ko) | 2017-03-14 | 2022-11-01 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| KR20240011880A (ko) | 2017-12-07 | 2024-01-26 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| JP2021521118A (ja) | 2018-04-10 | 2021-08-26 | アテア ファーマシューティカルズ， インコーポレイテッド | 肝硬変を伴うｈｃｖ感染患者の治療 |
| US20210353660A1 (en) * | 2018-10-04 | 2021-11-18 | Octagon Therapeutics Inc. | Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs |
| US12419902B2 (en) | 2019-03-31 | 2025-09-23 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
| CN114641299A (zh) | 2020-01-27 | 2022-06-17 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AR121356A1 (es) | 2020-02-18 | 2022-05-11 | Gilead Sciences Inc | Compuestos antivirales |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN118994170A (zh) | 2020-03-12 | 2024-11-22 | 吉利德科学公司 | 制备1'-氰基核苷的方法 |
| CN111548384B (zh) * | 2020-03-29 | 2021-04-27 | 常州安蒂卫生物科技有限公司 | 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药 |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| US10988503B1 (en) * | 2020-05-06 | 2021-04-27 | Nantong Weishun Biotechnology Co., Ltd | Six-membered ring-containing nucleoside compound and preparation method thereof |
| EP4157272B1 (en) | 2020-05-29 | 2025-07-02 | Gilead Sciences, Inc. | Remdesivir for the treatment of viral infections |
| US11939347B2 (en) | 2020-06-24 | 2024-03-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and uses thereof |
| WO2022038539A2 (en) | 2020-08-18 | 2022-02-24 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
| SI4204421T1 (sl) | 2020-08-27 | 2024-07-31 | Gilead Sciences, Inc., | Spojine in postopki za zdravljenje virusnih okužb |
| JP2024514825A (ja) * | 2021-04-09 | 2024-04-03 | エモリー ユニバーシティー | 抗ウイルス剤としてのヌクレオシド及びヌクレオチドアナログ |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| KR20240022574A (ko) | 2021-06-17 | 2024-02-20 | 아테아 파마슈티컬즈, 인크. | 유리한 항-hcv 조합 요법 |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| EP4320128A1 (en) | 2022-03-02 | 2024-02-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| CA3245459A1 (en) | 2022-03-15 | 2023-09-21 | Rome Therapeutics, Inc. | COMPOUNDS AND METHODS FOR TREATING A DISEASE |
| WO2024016639A1 (zh) * | 2022-07-21 | 2024-01-25 | 华创合成制药股份有限公司 | 一种抗病毒感染的化合物及其制备方法和用途 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024169774A2 (en) * | 2023-02-17 | 2024-08-22 | Ascletis BioScience Co., Ltd | Nucleoside and nucleotide analogs, methods of making and methods of use thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| NO171507C (no) | 1988-11-21 | 1993-03-24 | Syntex Inc | Analogifremgangsmaate ved fremstilling av terapeutisk aktive nukleotidderivater |
| DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
| ATE167679T1 (de) | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
| CA2389745C (en) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| CN1427722A (zh) | 2000-02-18 | 2003-07-02 | 希拉生物化学股份有限公司 | 用核苷类似物治疗或预防黄病毒感染的方法 |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| KR20040028657A (ko) | 2000-10-18 | 2004-04-03 | 파마셋, 리미티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드 |
| CN1137132C (zh) * | 2000-12-14 | 2004-02-04 | 华东理工大学 | 一种氰基呋喃核苷化合物及其制备方法 |
| AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| EP1355916B1 (en) | 2001-01-22 | 2007-01-10 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| US7321033B2 (en) * | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
| KR20050048544A (ko) | 2002-06-28 | 2005-05-24 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용의 변형된 2' 및3'-뉴클레오사이드 프로드럭 |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| JPWO2004058959A1 (ja) * | 2002-12-26 | 2006-04-27 | 日本新薬株式会社 | ＰＮＰａｓｅの製造法 |
| EP2345658A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| PE20050249A1 (es) | 2003-07-25 | 2005-06-01 | Aventis Pharma Gmbh | Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos |
| MX2007000803A (es) | 2004-07-21 | 2007-04-02 | Pharmasset Inc | Preparacion de 2-desoxi-2-fluoro-d-ribofuranosil pirimidinas y purinas alquil-sustituidas y sus derivados. |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| CA2673649A1 (en) | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| WO2008089105A2 (en) | 2007-01-12 | 2008-07-24 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP2155758B1 (en) | 2007-05-10 | 2012-08-22 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro[3,4-d]dioxolane compounds for use in the treatment of viral infections and cancer |
| GB0709791D0 (en) | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
| JO3027B1 (ar) * | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
-
2012
- 2012-04-13 BR BR112013026219A patent/BR112013026219A2/pt not_active IP Right Cessation
- 2012-04-13 US US13/447,017 patent/US8877733B2/en active Active
- 2012-04-13 JP JP2014505381A patent/JP6043338B2/ja not_active Expired - Fee Related
- 2012-04-13 KR KR1020137029678A patent/KR20140019832A/ko not_active Withdrawn
- 2012-04-13 CA CA2830689A patent/CA2830689A1/en not_active Abandoned
- 2012-04-13 AU AU2012242517A patent/AU2012242517B2/en not_active Ceased
- 2012-04-13 EP EP12716969.6A patent/EP2697241B1/en active Active
- 2012-04-13 ES ES12716969T patent/ES2744587T3/es active Active
- 2012-04-13 MX MX2013011915A patent/MX2013011915A/es not_active Application Discontinuation
- 2012-04-13 CN CN2012800181025A patent/CN103476783A/zh active Pending
- 2012-04-13 EA EA201391264A patent/EA201391264A1/ru unknown
- 2012-04-13 WO PCT/US2012/033675 patent/WO2012142523A2/en not_active Ceased
-
2013
- 2013-10-02 IL IL228680A patent/IL228680A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014514308A5 (enExample) | ||
| JP2011518835A5 (enExample) | ||
| JP2012517444A5 (enExample) | ||
| JP2011521903A5 (enExample) | ||
| JP2013538230A5 (enExample) | ||
| ME02656B (me) | 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje | |
| HRP20150359T1 (hr) | 1'-supstituirani karba-nukleozidni analozi za antivirusnu terapiju | |
| JP2013514359A5 (enExample) | ||
| JP2010539241A5 (enExample) | ||
| CA2553879A1 (en) | Viral polymerase inhibitors | |
| RU2483073C2 (ru) | Фосфадиазиновые ингибиторы iv полимеразы hcv | |
| JP2011511841A5 (enExample) | ||
| JP2012504132A5 (enExample) | ||
| JP2012512169A5 (enExample) | ||
| JP2012504632A5 (enExample) | ||
| JP2014503516A5 (enExample) | ||
| RU2015123641A (ru) | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний | |
| JP2012504126A5 (enExample) | ||
| JP2011521965A5 (enExample) | ||
| JP2012504129A5 (enExample) | ||
| JP2012519691A5 (enExample) | ||
| JP2011520906A5 (enExample) | ||
| JP2015525220A5 (enExample) | ||
| AR066165A1 (es) | Metodos de tratamiento de una infeccion viral de la familia flaviviridae, composiciones para el tratamiento de una infeccion viral de la familia flaviviridae y ensayos de control para identificar composiciones para el tratamiento de una infeccion viral de la familia flaviviridae | |
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |